Background. Hypertrophic cardiomyopathy (HCM) is a common genetic cardiovascular disease with a diverse clinical spectrum which often includes functional disability due to progressive heart failure symptoms at any age. Assessment of symptom severity may be highly subjective and encumbered by the heterogenous clinical presentation of HCM. Plasma B-type natriuretic peptide (BNP) has been used widely as an objective marker for the severity of heart failure and clinical outcome predominantly in coronary heart disease with ventricular dilatation and systolic dysfunction. We considered the possibility that BNP would be an accurate and independent predictor of heart failure severity in HCM, a disease characterized by intact ventricular function in the absence of chamber dilatation. Methods. We prospectively assessed plasma BNP as a quantitative clinical marker of heart failure severity in 107 consecutive HCM patients. Results. BNP showed a statistically significant relationship to the magnitude of functional limitation assessed by New York Heart Association (NYHA) functional class: I: 136 ± 159 pg/ml; II: 338 ± 439 pg/ml; III/IV: 481 ± 334 pg/ml (p < 0.001). Multivariable analysis showed BNP was independently related to NYHA functional class (p = 0.003), as well as age (p = 0.0001) and left ventricular wall thickness (p = 0.0001). BNP power was considerable both in distinguishing patients with and without heart failure symptoms, or for differentiating between no (or only mild) symptoms and severe symptoms (area under receiver opearting curve = 0.75 and 0.83, respectively). A BNP cut-off value > 200 pg/ml was the most reliable predictor of heart failure symptoms with positive and negative predictive values of 65% and 79%, respectively. Conclusions. Plasma BNP is independently related to the presence and magnitude of heart failure-related symptoms in patients with HCM. The clinical power of BNP as a marker for heart failure in HCM is, however, restricted by the overlap in BNP values between symptom-related subgroups, due largely to the important confounding variables of advancing age and substantial left ventricular wall thickness characteristic of this heterogeneous disease.
Background: Mutations in myosin binding protein C (MYBPC3) represent the most common genetic cause of hypertrophic cardiomyopathy (HCM). MYBPC3-HCM has been associated with late onset of disease and benign course. Here, we determine the frequency, spectrum, and phenotype associated with MYBPC3-HCM in a cohort of unrelated patients evaluated at a single tertiary outpatient center. Methods: DNA was obtained from 389 unrelated HCM patients and analyzed for mutations in all 34 protein coding exons of MYBPC3 using polymerase chain reaction, denaturing high performance liquid chromatography, and direct DNA sequencing. Clinical data were extracted from patient records blinded to genotype. Results: Seventy-six patients (19.5%) were identified with 49 MYBPC3 mutations: 24 missense, 15 frameshift, 6 premature stop, 3 splice-site, and 1 in-frame deletion. Mutation type did not influence the clinical phenotype. Compared to patients without MYBPC3 mutations, patients with MYBPC3-HCM were younger at diagnosis (35.4 ± 15 years vs 42.7 ± 19 years, p = 0.002), more often had a family history of HCM (44.7% vs 27.2%, p = 0.004), and more often received an ICD (26.3% vs 12.8%, p = 0.003). When comparing patients with single MYBPC3 mutations (n=67) to those with single mutations involving either the beta myosin heavy chain (MYH7) or the light chains comprising the thick filament (n=60), there was no difference in age, symptoms at presentation, or degree of hypertrophy. However, patients with MYBPC3 mutations were less likely to undergo surgical myectomy than patients with thick filament mutations (34% vs 55%, p = 0.02). Conclusion: This study represents a comprehensive mutational analysis of the most common HCM-causing gene, MYBPC3, in the largest cohort of unrelated patients. Nearly 1 in 5 patients presenting to this tertiary HCM center had MYBPC3 mutations. Contrary to genotype-phenotype correlations derived from family studies, unrelated patients with MYBPC3-HCM were diagnosed at a younger age than those patients with no MYBPC3 mutation. Moreover, the only difference in phenotypic expression between MYBPC3-HCM and thick filament-HCM was likelihood of surgical myectomy.
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Mechanisms Objectives; Septal myectomy provides excellent outcomes for most patients with severe obstructive hypertrophic cardiomyopathy (HCM). However, in a few patients, left ventricular outflow tract obstruction (LVOTO) may recur or persist after myectomy, requiring repeat myectomy. We reviewed this subset to assess the mechanisms for recurrence or persistence of LVOTO. Methods; From 1975 to July 2003, 610 septal myectomies were performed by the authors for obstructive HCM; 13 of these were repeat myectomies for recurrent or persistent LVOTO after myectomies performed at our institution (n=6) or elsewhere (n=7). Six patients were age 16 years or younger at the reoperation. The mean interval between initial myectomy and repeat myectomy was 5.0+/-3.7 years. Results; At reoperation, mechanisms for obstruction included septal hypertrophy at mid-ventricular level (n=8), anomalous papillary muscles (n=3), and incomplete subaortic resection at the initial operation (n=11). Mean intraoperative peak systolic pressure gradients decreased from 68+/-34 to 6.9+/-5.1 mmHg after repeat myectomy. No mitral valve replacement was performed. An iatrogenic ventricular septal defect in one patient was successfully repaired. Mean follow-up was 5.8 years. There were no early deaths; one patient died 11 years after repeat myectomy at age 81. All surviving patients were in NYHA functional class I or II and free of significant LVOTO. Conclusions; Dynamic LVOTO may recur or persist after classic septal myectomy in a small number of patients. Repeat myectomy can be performed with excellent outcomes. Need for reoperation may be reduced with current surgical approaches which include a more extended resection of the mid-ventricular septum, relief of papillary muscle anomalies, and routine use of intraoperative transesophageal echocardiography.
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Coronary Microvascular Dysfunction and Long-Term Left Ventricular Remodeling in Hypertrophic Cardiomyopathy
